Neil W Gibson of OSI Pharmaceuticals

Jeffrey Settleman,  Harvard Medical School and MGH Cancer Center

David Bailey of Chemoventures

N Claude Cohen of Synergix

-View All Webcasts

FDA Adds Depression as Possible Side Effect of Cholesterol Meds

The FDA approved a label change for cholesterol drugs Vytorin (ezetimibe/simvastatin; Merck/Schering-Plough Pharmaceuticals) and Zetia (ezetimibe; Merck/Schering-Plough Pharmaceuticals), adding depression as a possible side effect. (2/14) CNNMoney.com